Site Meter

Wednesday, January 6, 2010

Dimebon Clinical Trial -- Mom Gets In


By Bob DeMarco
Alzheimer's Reading Room


Today, Dorothy started on the medication for the Dimebon clinical trial.

Dimebon Clinical Trial  -- Mom Gets In

There is no way to know at this time if she is receiving Dimebon or the placebo. The odds of getting one or the other are 50-50. Like flipping a coin.


If you go to Clinical Trials.gov and put this protocol number in you can find the Dimebon clinical trail that we are enrolled in: B1451006

Or you can take this short cut -- go here.

As I mentioned previously, I took my mother off Aricept back in early November to qualify for this trial. I am now convinced that Aricept did work for my mother. This is based on some not so subtle changes I noticed in her behavior after she was off the Aricept. I will explain this in a separate article.

I wanted this particular Dimebon clinical trial for a long list of reasons. I'll get to these at another time. I decided the combination of Namenda and Dimebon is the best way to go for us. My mother currently takes Namenda once a day -- 10 mg.

I should note that this particular clinical trial is for patients with -- Moderate To Severe Alzheimer's Disease. My mother scored a 12 on the Mini-Mental State Examination (MMSE). This is compared to a 19 a few years ago. The slide has been slow but steady in my view.

Some of you already enrolled in a Dimebon clinical trial might find this of interest. My mother will be taking 20 mg of Dimebon, three times a day. A pretty healthy dose of medication.

The next couple of weeks are critical to see if she experiences any bad side effects from the drug.

From my perspective, I don't have any expectations. I prefer to wait and see what happens and then deal with those circumstances as they arise.

I will be mildly disappointed if my mother ends up on the placebo. As many of you know, I studied risk in graduate school. Let me put it this way, I wouldn't bet the ranch if the odds of winning were 50-50. But in this case, the Dimebon clinical trial, the only real downside is disappointment. I'll weigh that against do nothing. Really can't lose here.

Hope to win.

Now that my mother is in the clinical trial and taking the medication, I won't have anything additional to say about the experience for the next 26 weeks or longer.

I really don't think I could tell you anything, anyway. My mother is a sample of one, and that is not statistically significant. If she is on Dimebon and nothing good happens I won't know for 26 weeks. If she is on the placebo, I won't know that for certain for 26 weeks.

If I see something positive happen, I can admit now that I will dying to write about it and let everyone know. I'll find a way to resist that temptation until I think it is appropriate to say something.

Let me say this once more. I have no real expectation going in. Obviously, I am hoping for the best, but I am not expecting a miracle.

I think the simple fact that we are in the trial tells you everything you would ever need to know about my opinion on this trial. I believe in clinical trials. I believe everyone dealing with Alzheimer's should investigate and consider entering a clinical trial.

If my mother was younger it is possible that we would have entered a clinical trial earlier. There were one or two that interested me but she was too old. There were one or two that I investigated thoroughly and passed on for various reasons.

I am not a doctor. I am not a scientist. So my opinion is not worth anymore than anyone else that investigates and decides.

Well that is it for now. However, as I close I think I might have lied a little bit. I am a little excited and a little more hopeful than usual. Just can't help myself.

Advice and Insight into Alzheimer's and Dementia

Bob DeMarco
Bob DeMarco is the Founder of the Alzheimer's Reading Room and an Alzheimer's caregiver. The ARR knowledge base contains more than 3,811 articles with more than 306,100 links on the Internet. Bob lives in Delray Beach, FL.

Original content Bob DeMarco, Alzheimer's Reading Room